Loading market dashboard
Altimmune, Inc.
ALTHealthcareNASDAQUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
Altimmune NASDAQ: ALT executives said the company is preparing to begin enrolling patients in the second half of the year for a Phase 3 trial of pemvidutide in metabolic dysfunction-associated steatohepatitis, or MASH, while also awaiting data from related alcohol-associated liver disease programs.
Lilly's Retevmo (selpercatinib) demonstrated an 83% reduction in the risk of disease recurrence or death as adjuvant therapy for people with ea
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced new data from its rare liver disease programs. Late-breaking result
“Best of EASL” oral presentation highlights meaningful reductions in triglycerides, cholesterol, and blood pressure, along with improvements in key metabolic risk factors
GAITHERSBURG, Md., May 27, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that management will participate in the following upcoming investor conferences:
Concurrent improvement across key non-invasive tests underscores convergence of pemvidutide effects on MASH disease activity and fibrosis AI-based digital pathology analyses further demonstrate antifibrotic effects of pemvidutide at 24 weeks GAITHERSBURG, Md., May 27, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that new analyses of data from the IMPACT Phase 2b trial demonstrated that treatment with pemvidutide, an investigational, balanced 1:1 glucagon/GLP-1 dual receptor agonist, is associated with concurrent improvements across multiple non-invasive tests (NITs) of metabolic dysfunction-associated steatohepatitis (MASH) activity and fibrosis.
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Hepcludex (bulevir
ALT advances pemvidutide in MASH, AUD and ALD, with phase III plans and promising liver disease data fueling investor focus.
ALT posts a narrower Q1 loss as pemvidutide advances in MASH, AUD and ALD studies, with the cash runway now expected to extend into 2029.
Altimmune, Inc. (ALT) Q1 2026 Earnings Call Transcript
Altimmune NASDAQ: ALT said it has strengthened its balance sheet and is preparing to begin a global Phase 3 trial of pemvidutide in metabolic dysfunction-associated steatohepatitis, or MASH, in the second half of 2026, as the company reported first-quarter financial results and provided updates across its liver disease pipeline.
Initiation of PERFORMA Phase 3 MASH trial planned for second half 2026 $535 million in cash, cash equivalents and short-term investments as of April 30, 2026 Webcast to be held today at 8:30 a.m. ET GAITHERSBURG, Md.
Abstract presenting 48-week IMPACT Phase 2b efficacy and safety data selected for inclusion in “Best of EASL 2026” by EASL
GAITHERSBURG, Md., May 06, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that it will report its first quarter 2026 financial results on Wednesday, May 13, 2026.
Ticker Change Reflects the Company's Continued Evolution Across Payments, Tokenization and AI-Driven Infrastructure LAS VEGAS, NV / ACCESS Newswire / April 29, 2026 / AI Financial Corporation (NASDAQ:AIFC)(FRA:5AR1) ("AiFi" or the "Company"), formerly ALT5 Sigma Corporation (NASDAQ:ALTS), a fintech company providing blockchain-powered payment, trading, and settlement infrastructure for digital assets, today announced that its common stock will begin trading under its new corporate name and Nasdaq ticker symbol, AIFC, effective at the open of market trading today, Wednesday, April 29, 2026. The Company's common stock ceased trading under the ticker symbol ALTS following after-market trading on Tuesday, April 28, 2026, and now trades under the new ticker symbol AIFC.
$225 million funded at closing, with an additional $225 million warrant tranche Financing funds operations through anticipated Phase 3 MASH 52-week data readout Financing was led by Deep Track Capital, with participation from TCGX, Viking Global Investors, RA Capital Management, and other new and existing investors GAITHERSBURG, Md., April 27, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced the closing of its previously announced underwritten public offering consisting of (i) 64,250,000 shares of its common stock and 64,250,000 accompanying common stock warrants to purchase shares of common stock or pre-funded warrants in lieu thereof and (ii) in lieu of common stock, to certain investors that so choose, pre-funded warrants to purchase an aggregate of up to 10,750,000 shares of its common stock and 10,750,000 accompanying common stock warrants to purchase shares of common stock or pre-funded warrants in lieu thereof, each at an exercise price of $0.001 per pre-funded warrant.
Altimmune, Inc. (NASDAQ: ALT - Get Free Report) has been given an average rating of "Moderate Buy" by the ten analysts that are currently covering the firm, Marketbeat.com reports. Two investment analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation and seven have issued a buy recommendation on the company.
ALT's 2026 hinges on pemvidutide, with key readouts, a phase III start, and funding strategy set to shape investor sentiment.
Altimmune bets big on pemvidutide across MASH, AUD and ALD, but with one drug driving value, upcoming trials could make or break the story.
ALT heads into a high-stakes 2026 as pemvidutide drives key phase III and mid-stage catalysts that could reshape its valuation-or risk setbacks.
GAITHERSBURG, Md. , April 22, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced the pricing of its previously announced underwritten public offering consisting of (i) 64,250,000 shares of its common stock and accompanying common stock warrants to purchase an aggregate of 64,250,000 shares of common stock (or pre-funded warrants in lieu thereof) and (ii) in lieu of common stock, to certain investors that so choose, pre-funded warrants to purchase an aggregate of up to 10,750,000 shares of its common stock and accompanying common stock warrants to purchase an aggregate of 10,750,000 shares of common stock (or pre-funded warrants in lieu thereof), at an exercise price of $0.
GAITHERSBURG, Md., April 22, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced the pricing of its previously announced underwritten public offering consisting of (i) 64,250,000 shares of its common stock and accompanying common stock warrants to purchase an aggregate of 64,250,000 shares of common stock (or pre-funded warrants in lieu thereof) and (ii) in lieu of common stock, to certain investors that so choose, pre-funded warrants to purchase an aggregate of up to 10,750,000 shares of its common stock and accompanying common stock warrants to purchase an aggregate of 10,750,000 shares of common stock (or pre-funded warrants in lieu thereof), at an exercise price of $0.001 per pre-funded warrant. The common stock and pre-funded warrants are being sold in combination with an accompanying common stock warrant to purchase one share of common stock (or pre-funded warrant in lieu thereof) issued for each share of common stock or pre-funded warrant sold. The accompanying common stock warrant has an exercise price of $3.00 per share, is immediately exercisable from the date of issuance and will expire upon the earlier of (i) the fifth anniversary of the original issuance date and (ii) forty-five days following the Company's public announcement of a successful data readout of its Phase 3 trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (“MASH”). The combined offering price of each share of common stock and accompany common stock warrant is $3.00. The combined offering price of each pre-funded warrant and accompanying common stock warrant is $2.999. The offering is expected to close on or about April 24, 2026, subject to satisfaction of customary closing conditions.
GAITHERSBURG, Md., April 22, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced it has commenced an underwritten public offering of shares of its common stock and accompanying common stock warrants to purchase an equivalent number of shares of its common stock (or pre-funded warrants in lieu thereof), and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock and accompanying common stock warrants to purchase shares of its common stock (or pre-funded warrants in lieu thereof). All of the shares, pre-funded warrants and accompanying common stock warrants to be sold in the proposed public offering are being offered by Altimmune. The proposed public offering is subject to market and other conditions, and there can be no assurance as to whether or when the proposed public offering may be completed or as to the actual terms of the offering.
Rebrand aligns next phase of platform strategy across payments, tokenization, and AI- driven financial infrastructure LAS VEGAS, NV / ACCESS Newswire / April 22, 2026 / ALT5 Sigma Corporation (NASDAQ:ALTS)(FRA:5AR1) (the "Company" or "ALT5"), a fintech company providing blockchain-powered payment, trading, and settlement infrastructure for digital assets, today announced plans to rebrand as AI Financial Corporation (AiFi) and change its Nasdaq ticker symbol to AIFC. The Company expects its common stock to begin trading under the new ticker symbol AIFC on The Nasdaq Capital Market in the near term.
Altimmune (NASDAQ: ALT) shareholders approved all proposals presented at the company's virtual annual meeting on April 16, 2026, including the election of nine directors and amendments that expand the company's authorized common stock and employee stock purchase plan share reserve. Meeting format and attendance Jerome Durso, Chairman of the Board, called the meeting to order and
ALT5's core fintech platform continued to scale in 2025, supported by growth across payments, trading, and settlement processing of approximately $3.5 billion in transaction volume during the year ALT5 strengthened its operating foundation through compliance restoration, governance upgrades, and continued platform expansion following the acquisition of Mswipe Recent initiatives demonstrate the Company's strategy to extend its core institutional infrastructure into emerging payment and settlement use cases, including AI-enabled commerce LAS VEGAS, NV / ACCESS Newswire / April 13, 2026 / ALT5 Sigma Corporation (NASDAQ:ALTS)(FRA:5AR1) (the "Company" or "ALT5"), a fintech company that maintains a strategic digital asset treasury and provides blockchain-powered payment, trading, and settlement infrastructure for digital assets, including card-based payment programs, today announced its financial results for the full year ended December 27, 2025. The Company's 2025 results reflect continued growth in its core fintech operations, the contribution from the Mswipe acquisition, and ongoing progress in strengthening the Company's strategic foundation.
TNF Pharmaceuticals (NASDAQ: TNFA - Get Free Report) and Altimmune (NASDAQ: ALT - Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, dividends, institutional ownership, analyst recommendations, earnings and profitability. Risk and Volatility TNF Pharmaceuticals has a beta
Altimmune heads into a pivotal 2026 MASH race, betting its dual agonist pemvidutide can stand out in a crowded field as key catalysts and risks converge.
Altimmune heads into 2026 with high-stakes catalysts as pemvidutide drives its pipeline, but funding needs and dilution risk loom alongside key clinical readouts.
Altimmune's pemvidutide targets MASH with dual glucagon/GLP-1 biology, showing mid-stage promise as it advances toward a high-stakes phase III study.
Altimmune, Inc. appears undervalued on risk-adjusted NPV but faces severe funding and competitive headwinds. Pemvidutide's Phase 3 MASH program is ambitious, requiring significant capital, and now includes titration, impacting its tolerability edge. The pipeline's AUD and ALD indications have negative risk-adjusted NPVs and further strain ALT's financial position.
Altimmune, Inc. (ALT) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Altimmune (NASDAQ: ALT) executives used the company's year-end 2025 results call to outline preparations for a pivotal Phase 3 program for pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH), while also providing updates on ongoing Phase 2 studies in alcohol use disorder (AUD) and alcohol-related liver disease (ALD) and reviewing year-end liquidity. Management frames pemvidutide's positioning in liver
